Here is how AxoGen (AXGN) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

NEW YORK, Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ( "Axogen" or the "Company" ) AXGN. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 06, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ( "Axogen" or the "Company" ) AXGN. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

U.S. stocks were mixed, with the Dow Jones index falling more than 200 points on Monday. Shares of Keurig Dr Pepper Inc. KDP fell sharply during Monday's session after the company announced the acquisition of JDE Peet's. Keurig Dr Pepper shares dipped 7.8% to $32.38 on Monday.

FDA delays Axogen's Avance Nerve Graft review by three months and sets a new PDUFA date for December 5. Axogen projects $219 million in revenue for FY25, with 17% growth despite the review extension. The market is reacting to Powell's speech. Learn how to time your next move. Details here →

FDA PDUFA goal date extended by three months FDA PDUFA goal date extended by three months ...

AxoGen (AXGN) delivered earnings and revenue surprises of +100.00% and +7.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?